Ethosuximide

Generic name: Pronounced as (eth oh sux' i mide)
Brand names
  • Zarontin®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 06/15/2017

Ethosuximide is used to control absence seizures (petit mal) (a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others). Ethosuximide is in a class of medications called anticonvulsants. It works by reducing abnormal electrical activity in the brain.

Ethosuximide comes as a capsule and as a syrup (liquid) to take by mouth. It is usually taken one or more times a day. Take ethosuximide at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ethosuximide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor will probably start you on a low dose of ethosuximide and gradually increase your dose, usually once every 4 to 7 days.

Ethosuximide may help to control your condition, but will not cure it. Continue to take ethosuximide even if you feel well. Do not stop taking ethosuximide without talking to your doctor, even if you experience side effects such as unusual changes in behavior or mood. If you suddenly stop taking ethosuximide, your seizures may worsen. Your doctor will probably decrease your dose gradually.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Before taking ethosuximide,

  • tell your doctor and pharmacist if you are allergic to ethosuximide, methsuximide (Celontin), or any other medications.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention antidepressants; other medications for seizures such as phenytoin (Dilantin) and valproic acid (Depakene, Depakote); medications for pain; sedatives; sleeping pills; or tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had mental illness or kidney or liver disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking ethosuximide, call your doctor.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking ethosuximide.

  • you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • ask your doctor about the safe use of alcohol while you are taking this medication.

  • you should know that your mental health may change in unexpected ways and you may become suicidal (thinking about harming or killing yourself or planning or trying to do so) while you are taking ethosuximide. A small number of adults and children 5 years of age and older (about 1 in 500 people) who took anticonvulsants such as ethosuximide to treat various conditions during clinical studies became suicidal during their treatment. Some of these people developed suicidal thoughts and behavior as early as one week after they started taking the medication. There is a risk that you may experience changes in your mental health if you take an anticonvulsant medication such as ethosuximide, but there may also be a risk that you will experience changes in your mental health if your condition is not treated. You and your doctor will decide whether the risks of taking an anticonvulsant medication are greater than the risks of not taking the medication. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: panic attacks; agitation or restlessness; new or worsening irritability, anxiety, or depression; acting on dangerous impulses; difficulty falling or staying asleep; aggressive, angry, or violent behavior; mania (frenzied, abnormally excited mood); talking or thinking about wanting to hurt yourself or to end your life; withdrawing from friends and family; preoccupation with death and dying; giving away prized possessions; or any other unusual changes in behavior or mood. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Ethosuximide may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • vomiting

    • diarrhea

    • stomach pain or cramps

    • loss of appetite

    • weight loss

    • swelling of the tongue

    • overgrowth of the gums

    • hiccups

    • drowsiness

    • dizziness

    • headache

    • suddenly awakening from sleep in a frightened state

    • difficulty concentrating

    • hair growth in unusual places

    • near-sightedness

    • vaginal bleeding

  • Some side effects may be serious. If you experience any of the following symptoms, or those mentioned in the SPECIAL PRECAUTIONS section, call your doctor immediately:

    • sore throat, fever, chills, and other signs of infection

    • joint pain or swelling

    • muscle pain

    • red, itchy rash, especially on the face

    • fever with no known cause

    • hives

    • blisters

  • Ethosuximide may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature, away from light, excess heat, and moisture (not in the bathroom). Do not allow the syrup to freeze.

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • nausea

  • vomiting

  • decreased alertness

  • slowed breathing

  • coma (loss of consciousness for a period of time)

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to ethosuximide.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Moxifloxacin.
Repaglinide Repaglinide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Repaglinide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin glargine.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Dolasetron.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Ethosuximide.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Ethosuximide.
Candesartan Candesartan The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Candesartan.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Cilostazol.
Clopidogrel Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ethosuximide.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Ethosuximide.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.
Magnesium Gluconate Magnesium Gluconate The risk or severity of hypotension can be increased when Ethosuximide is combined with Magnesium gluconate.
Magnesium Hydroxide Magnesium Hydroxide The risk or severity of hypotension can be increased when Ethosuximide is combined with Magnesium hydroxide.
Magnesium Oxide Magnesium Oxide The risk or severity of hypotension can be increased when Ethosuximide is combined with Magnesium oxide.
Miglitol Miglitol The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Miglitol.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Ethosuximide is combined with Naratriptan.
Olsalazine Olsalazine The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Olsalazine.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.
Penbutolol Penbutolol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Pentazocine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ethosuximide.
Potassium Potassium Potassium may increase the hyperkalemic activities of Ethosuximide.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Ethosuximide.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Ethosuximide.
Rizatriptan Rizatriptan The risk or severity of adverse effects can be increased when Ethosuximide is combined with Rizatriptan.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Ethosuximide is combined with Sumatriptan.
Tacrolimus Tacrolimus Tacrolimus may increase the immunosuppressive activities of Ethosuximide.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.
Zolmitriptan Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ethosuximide.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Famotidine.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ethosuximide.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ethosuximide.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Levofloxacin.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Ethosuximide.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Ethosuximide is combined with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Metronidazole.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.
Altretamine Altretamine Amphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cyclosporine Cyclosporine The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Cyclosporine.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ondansetron.
Enoxaparin Injection Enoxaparin Injection The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Enoxaparin.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Granisetron.
Olanzapine Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethosuximide.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Ethosuximide is combined with Alosetron.
Dofetilide Dofetilide Ethosuximide may increase the arrhythmogenic activities of Dofetilide.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Ethosuximide.
Eprosartan Eprosartan The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Eprosartan.
Hydroxychloroquine Hydroxychloroquine The therapeutic efficacy of Hydroxychloroquine can be decreased when used in combination with Ethosuximide.
Meloxicam Meloxicam The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Meloxicam.
Orlistat Orlistat Orlistat can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxcarbazepine.
Telmisartan Telmisartan The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Telmisartan.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Ethosuximide is combined with Zaleplon.
Anakinra Anakinra The metabolism of Ethosuximide can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.
Linezolid Linezolid The risk or severity of adverse effects can be increased when Ethosuximide is combined with Linezolid.
Rivastigmine Rivastigmine Ethosuximide may increase the bradycardic activities of Rivastigmine.
Trimipramine Trimipramine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Ethosuximide can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Perindopril Perindopril The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Perindopril.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Choline magnesium trisalicylate.
Sirolimus Sirolimus Ethosuximide may increase the immunosuppressive activities of Sirolimus.
Eplerenone Eplerenone The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Eplerenone.
Escitalopram Escitalopram The risk or severity of adverse effects can be increased when Escitalopram is combined with Ethosuximide.
Olmesartan Olmesartan The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Ethosuximide.
Zonisamide Zonisamide Ethosuximide may increase the arrhythmogenic activities of Zonisamide.
Adalimumab Injection Adalimumab Injection The metabolism of Ethosuximide can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Ethosuximide.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Dexmethylphenidate.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Atazanavir.
Almotriptan Almotriptan The risk or severity of adverse effects can be increased when Ethosuximide is combined with Almotriptan.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Ethosuximide.
Mefloquine Mefloquine The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ethosuximide.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Vardenafil.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ethosuximide.
Tegaserod Tegaserod The metabolism of Ethosuximide can be decreased when combined with Tegaserod.
Frovatriptan Frovatriptan The risk or severity of adverse effects can be increased when Ethosuximide is combined with Frovatriptan.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Ethosuximide can be increased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Ethosuximide is combined with Apomorphine.
Infliximab Injection Infliximab Injection The metabolism of Ethosuximide can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.
Duloxetine Duloxetine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Ethosuximide can be increased when combined with Norethisterone.
Trospium Trospium Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Ethosuximide is combined with Eszopiclone.
Ganciclovir Ganciclovir The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Ganciclovir.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin aspart.
Solifenacin Solifenacin Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Valganciclovir Valganciclovir The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Valganciclovir.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Voriconazole.
Dextroamphetamine Dextroamphetamine Amphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pramlintide Injection Pramlintide Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Pramlintide.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Exenatide Injection Exenatide Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Exenatide.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ibandronate.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Ethosuximide is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon.
Darifenacin Darifenacin Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Ethosuximide is combined with Fentanyl.
Pregabalin Pregabalin The therapeutic efficacy of Ethosuximide can be increased when used in combination with Pregabalin.
Phenylephrine Phenylephrine The risk or severity of hypertension can be decreased when Ethosuximide is combined with Phenylephrine.
Felbamate Felbamate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Felbamate.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin detemir.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Ethosuximide can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of adverse effects can be increased when Ethosuximide is combined with Rasagiline.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Imatinib.
Sitagliptin Sitagliptin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Sitagliptin.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Salbutamol.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ethosuximide.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin glulisine.
Lubiprostone Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ethosuximide.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Posaconazole.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Primaquine.
Aliskiren Aliskiren The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Aliskiren.
Darunavir Darunavir The serum concentration of Ethosuximide can be increased when it is combined with Darunavir.
Dimenhydrinate Dimenhydrinate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine Lisdexamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ethosuximide.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Sunitinib.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Lapatinib.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocetirizine.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Dasatinib.
Mexiletine Mexiletine Mexiletine may increase the arrhythmogenic activities of Ethosuximide.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Ethosuximide.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Toremifene.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethosuximide.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethosuximide.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Arsenic trioxide.
Mitoxantrone Injection Mitoxantrone Injection The metabolism of Ethosuximide can be increased when combined with Mitoxantrone.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Desvenlafaxine.
Nebivolol Nebivolol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Nebivolol.
Flecainide Flecainide Ethosuximide may increase the arrhythmogenic activities of Flecainide.
Certolizumab Injection Certolizumab Injection The metabolism of Ethosuximide can be increased when combined with Certolizumab pegol.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethosuximide.
Silodosin Silodosin The risk or severity of hypotension can be increased when Silodosin is combined with Ethosuximide.
Midazolam Midazolam The risk or severity of adverse effects can be increased when Ethosuximide is combined with Midazolam.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Ethosuximide is combined with Milnacipran.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ethosuximide.
Fesoterodine Fesoterodine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Degarelix.
Betaxolol Betaxolol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Iloperidone.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lacosamide.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Tolvaptan.
Dronedarone Dronedarone Ethosuximide may increase the arrhythmogenic activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethosuximide.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Ethosuximide.
Saxagliptin Saxagliptin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Saxagliptin.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Topotecan Topotecan Topotecan may increase the excretion rate of Ethosuximide which could result in a lower serum level and potentially a reduction in efficacy.
Golimumab Injection Golimumab Injection The metabolism of Ethosuximide can be increased when combined with Golimumab.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Pazopanib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Ethosuximide is combined with Vigabatrin.
Ulipristal Ulipristal The metabolism of Ethosuximide can be increased when combined with Ulipristal.
Levonorgestrel Levonorgestrel The metabolism of Ethosuximide can be increased when combined with Levonorgestrel.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxymorphone.
Liraglutide Injection Liraglutide Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Liraglutide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Ethosuximide can be increased when combined with Tocilizumab.
Fingolimod Fingolimod The metabolism of Fingolimod can be decreased when combined with Ethosuximide.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Eribulin.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethosuximide.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection Ethosuximide may increase the hepatotoxic activities of Acetaminophen.
Vilazodone Vilazodone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Vilazodone.
Denileukin Diftitox Injection Denileukin Diftitox Injection The metabolism of Ethosuximide can be decreased when combined with Aldesleukin.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Terbutaline.
Azilsartan Azilsartan The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Azilsartan medoxomil.
Linagliptin Linagliptin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Linagliptin.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Rilpivirine.
Potassium Iodide Potassium Iodide Potassium Iodide may increase the hyperkalemic activities of Ethosuximide.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Triptorelin.
Ruxolitinib Ruxolitinib Ruxolitinib may increase the bradycardic activities of Ethosuximide.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Vandetanib.
Clobazam Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Ethosuximide.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ethosuximide.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Crizotinib.
Cabergoline Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Ethosuximide.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiagabine.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Mirabegron.
Regorafenib Regorafenib Ethosuximide may increase the bradycardic activities of Regorafenib.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ethosuximide.
Lorcaserin Lorcaserin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Mecasermin.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Bedaquiline.
Tofacitinib Tofacitinib Ethosuximide may increase the bradycardic activities of Tofacitinib.
Alogliptin Alogliptin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Alogliptin.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.
Canagliflozin Canagliflozin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Canagliflozin.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Dabrafenib.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ethosuximide.
Vortioxetine Vortioxetine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Ketorolac Injection Ketorolac Injection The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Ethosuximide.
Dapagliflozin Dapagliflozin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Dapagliflozin.
Apremilast Apremilast The metabolism of Ethosuximide can be increased when combined with Apremilast.
Ceritinib Ceritinib Ethosuximide may increase the bradycardic activities of Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Ethosuximide can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Albiglutide.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Eslicarbazepine.
Empagliflozin Empagliflozin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Empagliflozin.
Hydrocodone Hydrocodone Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Dulaglutide.
Methamphetamine Methamphetamine Metamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tasimelteon.
Lanreotide Injection Lanreotide Injection Ethosuximide may increase the bradycardic activities of Lanreotide.
Secukinumab Injection Secukinumab Injection The metabolism of Ethosuximide can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Ethosuximide is combined with Risperidone.
Insulin Human Inhalation Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin human.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Lenvatinib.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Haloperidol.
Ivabradine Ivabradine Ethosuximide may increase the bradycardic activities of Ivabradine.
Amiloride Amiloride The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Amiloride.
Isavuconazonium Injection Isavuconazonium Injection The therapeutic efficacy of Isavuconazonium can be increased when used in combination with Ethosuximide.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Ethosuximide is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Ethosuximide.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Cariprazine.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin degludec.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Ethosuximide.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Ethosuximide may decrease the nephrotoxic activities of Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The metabolism of Ethosuximide can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Ethosuximide is combined with Brivaracetam.
Midodrine Midodrine Midodrine may increase the bradycardic activities of Ethosuximide.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Ethosuximide is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Ethosuximide is combined with Diphenhydramine.
Lixisenatide Injection Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Lixisenatide.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Ethosuximide.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Deutetrabenazine.
Safinamide Safinamide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Safinamide.
Midostaurin Midostaurin The metabolism of Ethosuximide can be decreased when combined with Midostaurin.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ethosuximide.
Semaglutide Injection Semaglutide Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Semaglutide.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Lofexidine Lofexidine The therapeutic efficacy of Ethosuximide can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ivosidenib.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ethosuximide.
Stiripentol Stiripentol The risk or severity of adverse effects can be increased when Ethosuximide is combined with Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Glasdegib.
Prucalopride Prucalopride The therapeutic efficacy of Prucalopride can be decreased when used in combination with Ethosuximide.
Magnesium Citrate Magnesium Citrate The risk or severity of hypotension can be increased when Ethosuximide is combined with Magnesium citrate.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Ethosuximide can be increased when combined with Emapalumab.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Ethosuximide is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of adverse effects can be increased when Ethosuximide is combined with Solriamfetol.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Entrectinib.
Pitolisant Pitolisant The serum concentration of Ethosuximide can be decreased when it is combined with Pitolisant.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Ethosuximide.
Phenytoin Injection Phenytoin Injection The serum concentration of Ethosuximide can be increased when it is combined with Phenytoin.
Fosphenytoin Injection Fosphenytoin Injection The serum concentration of Ethosuximide can be increased when it is combined with Fosphenytoin.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lasmiditan.
Calcium Acetate Calcium Acetate The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium acetate.
Cenobamate Cenobamate The serum concentration of Ethosuximide can be decreased when it is combined with Cenobamate.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Ethosuximide.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Ethosuximide.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of adverse effects can be increased when Fenfluramine is combined with Ethosuximide.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Fostemsavir.
Octreotide Octreotide The serum concentration of the active metabolites of Ethosuximide can be increased when Ethosuximide is used in combination with Octreotide.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Ethosuximide can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Relugolix.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Ethosuximide can be increased when combined with Drospirenone.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Viloxazine.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Ethosuximide.
Fenoprofen Fenoprofen The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Ethosuximide.
Indomethacin Indomethacin The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Ethosuximide.
Mefenamic Acid Mefenamic Acid The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Mefenamic acid.
Naproxen Naproxen The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Naproxen.
Tolmetin Tolmetin The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Ethosuximide.
Sulindac Sulindac The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Sulindac.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ethosuximide.
Phenobarbital Phenobarbital The metabolism of Phenobarbital can be decreased when combined with Ethosuximide.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Ethosuximide is combined with Levorphanol.
Primidone Primidone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Primidone.
Methsuximide Methsuximide Ethosuximide may increase the arrhythmogenic activities of Methsuximide.
Diethylpropion Diethylpropion Diethylpropion can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chlorpromazine Chlorpromazine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Ethosuximide is combined with Diazepam.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxazepam.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Ethosuximide is combined with Flurazepam.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Clorazepic acid.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.
Phenoxybenzamine Phenoxybenzamine The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Ethosuximide.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Amantadine.
Codeine Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Ethosuximide.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethosuximide.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Bromocriptine.
Tranylcypromine Tranylcypromine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tranylcypromine.
Phenelzine Phenelzine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenelzine.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Procarbazine.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ergoloid mesylate.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Prochlorperazine Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.
Thioridazine Thioridazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Trifluoperazine.
Sulfadiazine Sulfadiazine The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Sulfadiazine.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.
Oxybutynin Oxybutynin Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Maprotiline Maprotiline Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ibuprofen Ibuprofen The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Perphenazine.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluphenazine.
Phentermine Phentermine Phentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate Methylphenidate The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methylphenidate.
Amoxapine Amoxapine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
Sulfasalazine Sulfasalazine The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Sulfasalazine.
Carbamazepine Carbamazepine Carbamazepine may increase the Change in thyroid function activities of Ethosuximide.
Molindone Molindone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Molindone.
Methyldopa Methyldopa Ethosuximide may increase the bradycardic activities of Methyldopa.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Ethosuximide.
Prazosin Prazosin The risk or severity of hypotension can be increased when Prazosin is combined with Ethosuximide.
Cimetidine Cimetidine The serum concentration of Ethosuximide can be increased when it is combined with Cimetidine.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Ethosuximide is combined with Clonazepam.
Loperamide Loperamide Ethosuximide may increase the arrhythmogenic activities of Loperamide.
Promethazine Promethazine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Promethazine.
Meclofenamate Meclofenamate The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Meclofenamic acid.
Nitrofurantoin Nitrofurantoin The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Nitrofurantoin.
Digoxin Digoxin Ethosuximide may increase the arrhythmogenic activities of Digoxin.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Chloroquine.
Quinine Quinine The risk or severity of adverse effects can be increased when Quinine is combined with Ethosuximide.
Triamterene Triamterene The risk or severity of hyperkalemia can be increased when Triamterene is combined with Ethosuximide.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Ethosuximide.
Isosorbide Isosorbide The metabolism of Isosorbide can be increased when combined with Ethosuximide.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Ethosuximide.
Desipramine Desipramine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Amitriptyline Amitriptyline The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Amitriptyline.
Imipramine Imipramine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Quinidine Quinidine Quinidine may increase the arrhythmogenic activities of Ethosuximide.
Procainamide Procainamide Ethosuximide may increase the arrhythmogenic activities of Procainamide.
Isoniazid Isoniazid The metabolism of Ethosuximide can be decreased when combined with Isoniazid.
Rifampin Rifampin The metabolism of Ethosuximide can be increased when combined with Rifampicin.
Disopyramide Disopyramide Ethosuximide may increase the arrhythmogenic activities of Disopyramide.
Valproic Acid Valproic Acid The serum concentration of Valproic acid can be decreased when it is combined with Ethosuximide.
Tamoxifen Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Ethosuximide.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide.
Methimazole Methimazole The metabolism of Ethosuximide can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Chlorpropamide.
Tolbutamide Tolbutamide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Tolbutamide.
Tolazamide Tolazamide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Tolazamide.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ethosuximide.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Ethosuximide is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Ethosuximide can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Ethosuximide.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Cyproheptadine Cyproheptadine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Meclizine.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Hydrochlorothiazide.
Dantrolene Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Ethosuximide.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethosuximide.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.
Disulfiram Disulfiram The metabolism of Ethosuximide can be decreased when combined with Disulfiram.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of bradycardia can be increased when Ethosuximide is combined with Propranolol.
Pseudoephedrine Pseudoephedrine Pseudoephedrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nortriptyline Nortriptyline Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
Spironolactone Spironolactone The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ethosuximide.
Amphotericin B Injection Amphotericin B Injection Ethosuximide may decrease the nephrotoxic activities of Amphotericin B.
Mercaptopurine Mercaptopurine Ethosuximide may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.
Nadolol Nadolol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Nadolol.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Ethosuximide is combined with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Ethosuximide is combined with Nalbuphine.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ethosuximide.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimethobenzamide.
Flavoxate Flavoxate Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Fluorouracil.
Colchicine Colchicine The metabolism of Ethosuximide can be increased when combined with Colchicine.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Acetazolamide.
Cefotaxime Injection Cefotaxime Injection The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Cefotaxime.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Ethosuximide is combined with Pyrantel.
Captopril Captopril The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Captopril.
Metoprolol Metoprolol The risk or severity of bradycardia can be increased when Metoprolol is combined with Ethosuximide.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ethosuximide.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiothixene.
Aspirin Aspirin The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Acetylsalicylic acid.
Salsalate Salsalate The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Salsalate.
Chlorambucil Chlorambucil The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Chlorambucil.
Alprazolam Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Ethosuximide.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Ethosuximide.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Ethosuximide is combined with Triazolam.
Dicyclomine Dicyclomine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Ethosuximide may increase the arrhythmogenic activities of Hyoscyamine.
Propantheline Propantheline Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Ethosuximide.
Diltiazem Diltiazem Ethosuximide may increase the arrhythmogenic activities of Diltiazem.
Nifedipine Nifedipine Nifedipine may increase the arrhythmogenic activities of Ethosuximide.
Timolol Timolol The risk or severity of adverse effects can be increased when Ethosuximide is combined with Timolol.
Verapamil Verapamil Ethosuximide may increase the arrhythmogenic activities of Verapamil.
Atenolol Atenolol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Atenolol.
Pindolol Pindolol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Pindolol.
Diflunisal Diflunisal The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Diflunisal.
Piroxicam Piroxicam The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Ethosuximide.
Streptozocin Streptozocin The metabolism of Ethosuximide can be increased when combined with Streptozocin.
Glyburide Glyburide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Glyburide.
Glipizide Glipizide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Glipizide.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Indapamide.
Nafcillin Injection Nafcillin Injection The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Nafcillin.
Pentoxifylline Pentoxifylline Ethosuximide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Pentamidine.
Labetalol Labetalol The risk or severity of bradycardia can be increased when Labetalol is combined with Ethosuximide.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Leuprolide.
Ketoprofen Ketoprofen The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Ketoprofen.
Pimozide Pimozide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Pimozide.
Enalapril Enalapril The risk or severity of hyperkalemia can be increased when Enalapril is combined with Ethosuximide.
Flurbiprofen Flurbiprofen The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Flurbiprofen.
Amiodarone Amiodarone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Amiodarone.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ciprofloxacin.
Mesalamine Mesalamine The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Ethosuximide.
Diclofenac Diclofenac The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Ethosuximide.
Fluoxetine Fluoxetine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Nimodipine Nimodipine Ethosuximide may increase the arrhythmogenic activities of Nimodipine.
Clozapine Clozapine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Ethosuximide is combined with Estazolam.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ofloxacin.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation and hypotension can be increased when Clarithromycin is combined with Ethosuximide.
Benazepril Benazepril The risk or severity of hyperkalemia can be increased when Benazepril is combined with Ethosuximide.
Etodolac Etodolac The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Etodolac.
Felodipine Felodipine Ethosuximide may increase the arrhythmogenic activities of Felodipine.
Fosinopril Fosinopril The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Ethosuximide.
Nabumetone Nabumetone The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Ethosuximide.
Quinapril Quinapril The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Quinapril.
Ramipril Ramipril The risk or severity of hyperkalemia can be increased when Ramipril is combined with Ethosuximide.
Amlodipine Amlodipine Amlodipine may increase the arrhythmogenic activities of Ethosuximide.
Itraconazole Itraconazole The metabolism of Ethosuximide can be decreased when combined with Itraconazole.
Lisinopril Lisinopril The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Lisinopril.
Oxaprozin Oxaprozin The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Oxaprozin.
Sotalol Sotalol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Sotalol.
Bisoprolol Bisoprolol The therapeutic efficacy of Ethosuximide can be increased when used in combination with Bisoprolol.
Zolpidem Zolpidem Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The risk or severity of hypotension can be increased when Doxazosin is combined with Ethosuximide.
Terazosin Terazosin The risk or severity of hypotension can be increased when Terazosin is combined with Ethosuximide.
Isradipine Isradipine Isradipine may increase the arrhythmogenic activities of Ethosuximide.
Cisapride Cisapride The risk or severity of adverse effects can be increased when Ethosuximide is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Ethosuximide is combined with Gabapentin.
Venlafaxine Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ethosuximide.
Fluvoxamine Fluvoxamine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluvoxamine.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Ethosuximide is combined with Nefazodone.
Lamotrigine Lamotrigine Ethosuximide may increase the arrhythmogenic activities of Lamotrigine.
Losartan Losartan Losartan may increase the arrhythmogenic activities of Ethosuximide.
Tramadol Tramadol The risk or severity of CNS depression can be increased when Ethosuximide is combined with Tramadol.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Moexipril.
Nicardipine Nicardipine Ethosuximide may increase the arrhythmogenic activities of Nicardipine.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Ethosuximide is combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Ethosuximide can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Saquinavir.
Metformin Metformin The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Metformin.
Dalteparin Injection Dalteparin Injection The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Dalteparin.
Nisoldipine Nisoldipine Nisoldipine may increase the arrhythmogenic activities of Ethosuximide.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Ethosuximide is combined with Riluzole.
Acarbose Acarbose The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Acarbose.
Glimepiride Glimepiride Ethosuximide may increase the arrhythmogenic activities of Glimepiride.
Ritonavir Ritonavir The serum concentration of Ethosuximide can be increased when it is combined with Ritonavir.
Clomipramine Clomipramine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Clomipramine.
Zafirlukast Zafirlukast The metabolism of Ethosuximide can be decreased when combined with Zafirlukast.
Mirtazapine Mirtazapine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Trandolapril Trandolapril The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Ethosuximide.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.
Valsartan Valsartan The risk or severity of hyperkalemia can be increased when Valsartan is combined with Ethosuximide.
Insulin Lispro Injection Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin lispro.
Pramipexole Pramipexole Ethosuximide may increase the sedative activities of Pramipexole.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Ethosuximide is combined with Donepezil.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ethosuximide.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Azithromycin.
Carvedilol Carvedilol The risk or severity of bradycardia can be increased when Ethosuximide is combined with Carvedilol.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Ethosuximide is combined with Selegiline.
Sertraline Sertraline The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Sertraline.
Propafenone Propafenone The risk or severity of bradycardia can be increased when Ethosuximide is combined with Propafenone.
Irbesartan Irbesartan The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Irbesartan.
Tamsulosin Tamsulosin The risk or severity of hypotension can be increased when Tamsulosin is combined with Ethosuximide.
Ropinirole Ropinirole Ethosuximide may increase the sedative activities of Ropinirole.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Ethosuximide.
Paroxetine Paroxetine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.
Citalopram Citalopram The risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.
Efavirenz Efavirenz The serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.
Sildenafil Sildenafil The metabolism of Ethosuximide can be decreased when combined with Sildenafil.
Pioglitazone Pioglitazone The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Pioglitazone.
Celecoxib Celecoxib The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Ethosuximide.
Rosiglitazone Rosiglitazone The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Rosiglitazone.
Tolterodine Tolterodine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide Balsalazide The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Balsalazide.
Nateglinide Nateglinide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Nateglinide.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Galantamine.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Ethosuximide.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists